Evidence map›Paper›PMID 29941639›Full record

ArticleAntimicrobial agents and chemotherapy2018

Variability of Daptomycin MIC Values for Enterococcus faecium When Measured by Reference Broth Microdilution and Gradient Diffusion Tests.

Shelley A Campeau, Audrey N Schuetz, Peggy Kohner, Cesar A Arias, Peera Hemarajata, Jennifer Dien Bard, Romney M Humphries

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Non-susceptibility ofMicrobiology spectrum · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Antimicrobial Susceptibility Testing for Enterococci.Journal of clinical microbiology · 2022
    Review
  14. Article
  15. Article
  16. High-Dose Daptomycin and Clinical Applications.The Annals of pharmacotherapy · 2021
    Review
  17. Article
  18. Review
  19. The New, New Daptomycin Breakpoint forJournal of clinical microbiology · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Shelley A CampeauAccelerate Diagnostics, Tucson, Arizona, USA.
Audrey N SchuetzDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA.
Peggy KohnerDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA.
Cesar A AriasCenter for Antimicrobial Resistance and Microbial Genomics (CARMiG) and Division of Infectious Diseases, UTHealth McGovern Medical School, UTHealth School of Public Health, Houston, Texas, USA.
Peera HemarajataDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0001-6182-9136
Jennifer Dien BardDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
Romney M HumphriesAccelerate Diagnostics, Tucson, Arizona, USA rhumphries@axdx.com.
Accelerated Medical Diagnostics (United States) · USUniversity of Minnesota Rochester · USUniversidad El Bosque · COUniversity of California, Los Angeles · USUniversity of Southern California · US

Funding

The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
Molecular basis of the cefazolin inoculum effectR21AI143229 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2019 to 2020
$442k
NIAID NIH HHS K24 AI121296NIAID NIH HHS R01 AI134637NIAID NIH HHS R21 AI143229
6 · The paper itself

Abstract

Daptomycin has become a mainstay therapy for the treatment of serious vancomycin-resistant

Indexed as

Anti-Bacterial AgentsColony Count, MicrobialDaptomycinDrug Resistance, BacterialEnterococcus faeciumHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsDaptomycinbroth microdilutionCLSIdaptomycinEnterococcus faeciumEtestMIC test

Identifiers

PMID29941639
PMCPMC6125562
OpenAlexW2809959622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.